Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 13/20 | 0.38 |
| ▸ | EGFR | P00533 | 12/20 | 0.36 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.32 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21561513 | 0.87 | ERBB2 (0.41) | ERBB2EGFRTTBK1TTBK2AAK1 | |
| SCHEMBL13847669 | 0.86 | ERBB2 (0.40) | ERBB2EGFRTTBK1TTBK2AAK1 | |
| SCHEMBL18033869 | 0.77 | EGFR (0.35) | ERBB2EGFRLCKKDR | |
| SCHEMBL12883243 | 0.77 | ERBB2 (0.55) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL4813480 | 0.76 | ERBB2 (0.54) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL4821294 | 0.75 | MET (0.38) | ERBB2EGFRTTBK1TTBK2AAK1 | |
| SCHEMBL4820542 | 0.73 | ERBB2 (0.39) | ERBB2EGFRTTBK1TTBK2AAK1 | |
| SCHEMBL4820537 | 0.73 | ERBB2 (0.43) | ERBB2EGFRTTBK1TTBK2AAK1 | |
| SCHEMBL14017263 | 0.67 | MAPT (0.38) | KDRTSHR | |
| SCHEMBL24392121 | 0.67 | EGFR (0.37) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7432373-B2 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-10-07 | — | — | US | disclosed |
| US-7348325-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | MAP3K15, MAP3K5, STK25 | ERBB2 138/4885EGFR 908/4885TTBK1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.